2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 749

Childhood Takayasu Arteritis: Characteristics and Outcomes of a Mexican Cohort
Abstract Number: 746

Childhood-Onset Takayasu’s Arteritis (TAK) Is Clinically More Active, However Has Similar Cumulative Damage Compared to Adult-Onset TAK
Abstract Number: 1775

Cholesterol Sequestering in Macrophages Contributes to the Lipid Paradox in Chronic Arthritis
Abstract Number: 56

Choline Metabolite Is Associated with Inflammation in Arthritis in the Elderly
Abstract Number: 773

Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation
Abstract Number: 402

Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy
Abstract Number: 256

Chronic Musculoskeletal Pain and Its Initial Management in Children, Adolescents and Young Adults in the United States
Abstract Number: 1772

Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Abstract Number: 51

Cigarette Smoking Has Different Impacts on ACPA and RF Production Depending on Shared Epitope Allele Status in Japanese RA Patients; A Study with the Two Independent Japanese Cohorts (IORRA and KURAMA)
Abstract Number: 822

Cigarette Smoking Is a Risk Factor for ANCA-Associated Vasculitis
Abstract Number: 50

Circulating 25(OH)D, LL-37 and Antimicrobial Protein and Peptide (APP) Levels Are Altered Prior to Onset of Rheumatoid Arthritis
Abstract Number: 2421

Circulating CCR7loPD-1hi Follicular Helper T Cells Indicate Disease Activity and Glandular Inflammation in Patients with Primary Sjögren’s Syndrome
Abstract Number: 1661

Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1034

Circulating MicroRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment with Rituximab in Systemic Lupus Erythematosus
Abstract Number: 2005

Circulating Mitochondrial Danger-Associated Molecular Patterns as Novel Biomarkers of Disease Activity and Inflammation in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].